Hemlibra Approved in Taiwan for Treatment of Hemophilia A with Inhibitors: Chugai

Chugai Pharmaceutical said on December 4 that its hemophilia A treatment Hemlibra (emicizumab) has obtained approval in Taiwan for hemophilia A with factor VIII inhibitors. The bispecific factor IXa/X-directed antibody is indicated for the routine prophylaxis of bleeding episodes in...read more